Company intelligence / Profile preview
Medimetriks Pharmaceuticals, Inc.
Fairefield, NJ, United Statesmedimetriks.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Medimetriks has a robust commercial portfolio of dermatology and podiatry prescription brands. The company has successfully developed and commercialized products such as ozenoxacin cream for impetigo and difamilast for atopic dermatitis. Some assets have been divested after reaching key milestones. The company continues to expand its pipeline through licensing and acquisition strategies
- Therapeutic areas
- DermatologyInfectious Diseases
- Modalities
- Small molecules
- Industry
- Biotech
02
Drug pipeline
1 asset03
Partnerships
Ferrer Internacional S.A. – licensed ozenoxacin/Xepi for U.S.Otsuka Pharmaceutical Co., Ltd. – licensed difamilast/MM36/OPA‑15406 for U.S.Acrotech Biopharma – acquired MM36/difamilast asset from MedimetriksBiofrontera/Cutanea Life Sciences – acquired Xepi/ozenoxacin asset from Medimetriks
Beyond the preview
Go deeper on Medimetriks Pharmaceuticals, Inc..
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Medimetriks Pharmaceuticals, Inc..